FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Dysfunction topics
Dysfunction
Hypertension
Vascular Disease
Spinal Cord
Endothelial
Steoporosis
Endothelial Dysfunction
Nephropathy
Osteoporosis
Congestive Heart Failure
Theophylline
Sexual Dysfunction
Myocardial Infarction
Infarction
Cardiovascular Disease

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Dysfunction patents



      
           
This page is updated frequently with new Dysfunction-related patent applications. Subscribe to the Dysfunction RSS feed to automatically get the update: related Dysfunction RSS feeds. RSS updates for this page: Dysfunction RSS RSS


Date/App# patent app List of recent Dysfunction-related patents
08/14/14
20140228643
 System and method for implantation of lead and electrodes to the endopelvic portion of the pelvic nerves to treat pelvic floor/organ dysfunctions and pelvic neuropathic pain patent thumbnailnew patent System and method for implantation of lead and electrodes to the endopelvic portion of the pelvic nerves to treat pelvic floor/organ dysfunctions and pelvic neuropathic pain
A method for implanting an electrode to an endopelvic portion of a pelvic nerve includes the steps of: laparoscopically forming a first entry through the abdomen; introducing an applicator assembly through a second entry, the applicator assembly comprising a flexible introducer sleeve and a curved applicator tool disposed in the sleeve; manipulating a proximal end of the curved applicator tool to position a distal end of the curved applicator tool at an identified exposed nerve; and placing an electrode lead through the applicator assembly to the nerve.. .
08/14/14
20140228408
 Novel rock kinase inhibitors patent thumbnailnew patent Novel rock kinase inhibitors
The present invention relates to new kinase inhibitors, more specifically rock inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new rock inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.
08/14/14
20140228368
 Pyrimidine pde10 inhibitors patent thumbnailnew patent Pyrimidine pde10 inhibitors
The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (pde10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction..
08/07/14
20140221497
 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction patent thumbnailMethods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.. .
08/07/14
20140221456
 Targeting p63 to re-activate dormant reserve stem cells in olfactory epithelium patent thumbnailTargeting p63 to re-activate dormant reserve stem cells in olfactory epithelium
Disclosed herein is a method for activating a dormant epithelial stem cell, or population thereof, to a state of multipotency comprising, reducing the level of Δnp63 in the cell(s). The dormant epithelial stem cell(s) may be a horizontal basal cell (hbc) of the olfactory epithelium and the level of Δnp63 may be reduced by contacting the cell or population with an effective amount of one or more agents that downmodulate Δnp63.
08/07/14
20140221395
 Deuterium-enriched alkyl sulfonamides and uses thereof patent thumbnailDeuterium-enriched alkyl sulfonamides and uses thereof
The present invention is concerned with deuterium-enriched sulfonamides of formula 1, their pharmaceutically acceptable salts and methods of use thereof for the treatment of anxiety disorders including, general anxiety disorder (gad), panic disorder (pd), post-traumatic stress disorder (ptsd), social phobia (sp), health anxiety (hypochondriasis), depression, major depressive disorders, unipolar depression, bipolar i depression disorder, bipolar ii depression disorder, treatment-resistant depression, single episodic and recurrent major depressive disorders, depression in the medically ill, attention deficit hyperactivity disorder (adhd), attention deficit disorder (add), obsessive-compulsive disorder (ocd), obsessive-compulsive personality disorder (ocpd), autism spectrum disorder (asd), schizophrenia, psychosis, epilepsy, seizures, hot flashes due to menopause, age-related macular degeneration (amd), premature ejaculation, male erectile dysfunction, sexual dysfunction, obesity, eating disorders, bulimia nervosa, anorexia nervosa, angina, migraine, pain, nociception, sleep disorders, insomnia, fibromyalgia, alcohol withdrawal, autism, rett's syndrome, cyclothymic disorder, neural injury, neurodegenerative diseases, parkinson's disease, parkinson's disease psychosis, huntington disease, alzheimer's disease, frontotemporal dementia, cognitive impairment associated with age-related dementia, alzheimer's disease, schizophrenia, psychosis, depression, pain or discomfort associated with surgery and pain or discomfort associated with medical illness.. .
08/07/14
20140221385
 Combinations of serotonin receptor agonists for treatment of movement disorders patent thumbnailCombinations of serotonin receptor agonists for treatment of movement disorders
The present invention relates to the use of 5-ht1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, parkinson's disease and associated disorders thereof.
08/07/14
20140221371
 Heterocyclic compounds and their use as binding partners for 5-ht5 receptors patent thumbnailHeterocyclic compounds and their use as binding partners for 5-ht5 receptors
The invention relates to compounds of general formula (i), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-ht5 receptors for treating diseases that are modulated by a 5-ht5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions..
08/07/14
20140221350
 Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists patent thumbnailCyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists
The present invention provides 4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior..
08/07/14
20140220549
 Organ preservation and/or perfusion patent thumbnailOrgan preservation and/or perfusion
The present invention relates to a solution for preservation, perfusion, and/or reperfusion of an organ, especially the heart, for transplantation. The solution contains peptide inhibitor(s) of protein kinase c ε (pkc ε).
08/07/14
20140220052
Compositions and methods for wound healing, and for recruitment and activation of macrophages in injured tissues and in implanted biomaterials used for tissue engineering
The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes) and to healing of internal injuries. In particular, the present invention provides compositions and methods comprising molecules and nanoparticles with linked α-gal epitopes for induction of recruitment and activation of macrophages localized within or surrounding damaged and/or injured tissue.
07/31/14
20140214112
Implantable electroacupuncture device and method for treating erectile dysfunction
An implantable electroacupuncture device (iead) treats an erectile dysfunction condition of a patient through application of stimulation pulses applied at a target tissue location underlying, or in the vicinity of, at least one of acupoints bl52, bl23 or gv4. The iead comprises an implantable, coin-sized, self-contained, leadless electroacupuncture device having at least two electrodes attached to an outside surface of its housing.
07/31/14
20140213593
Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
In one aspect, the invention relates to bicyclic pyrazole compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/31/14
20140212908
Fetal pulmonary cells and uses thereof
Isolated mixed populations of fetal pulmonary cells, engineered three-dimensional tissue constructs of these cells, and uses thereof in identifying therapeutic agents which augment, repair, and/or replace dysfunctional native lung and to perform in vitro studies such as pharmaceutical screening, models for lung development and disease and characterization of chemical or mechanical injury are provided.. .
07/31/14
20140212425
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, the antibodies induce trogocytosis of b-cell antigens, such as cd19, cd20, cd21, cd22, cd79b, cd44, cd62l, or β7-integrin.
07/24/14
20140206707
6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/24/14
20140206698
Methods of diagnosing diastolic dysfunction
Diagnostic methods relating to a cardiac ventricular dysfunction are provided. In some embodiments, the diagnostic method is a method of diagnosing diastolic dysfunction in the absence of systolic dysfunction in a subject.
07/24/14
20140206676
Substituted 4-(1h-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of machr m1 receptors
In one aspect, the invention relates to substituted 4-(1h-pyrazol-4-yl)benzyl analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/24/14
20140206641
Remedy
It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis.
07/24/14
20140206612
Oral insulin therapies and protocol
Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.
07/24/14
20140205658
Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction
Compositions comprising one or more cytokines and methods for their use in inhibiting and/or alleviating effects of radiation therapy and/or chemotherapy and/or acute radiation syndrome in a subject in need thereof are provided.. .
07/24/14
20140205565
Compositions and methods for treating organ dysfunction
A method of retarding cellular senescence comprising (i) providing an extracellular matrix (ecm) composition comprising ecm from an adolescent tissue source, the ecm comprising an exogenously added cytokine, and (ii) administering ecm composition to an organ with cells exhibiting cellular senescence, wherein, the cytokine interacts with at least one molecule in the ecm composition and modulates ros production of the cells, whereby, the cellular senescence is abated.. .
07/17/14
20140200646
Compressible device
An electro-stimulation device for the treatment of anterior and posterior pelvic floor muscle dysfunction is reversibly compressible and is fully self-contained. The device requires no external power sources or control and may be inserted into the vagina or anus through the use of an applicator.
07/17/14
20140200403
Systems and methods for treating dysfunctions in the intestines and rectum that adapt to the anatomic form and structure of different individuals
A family of barrel structures is provided in a kit. Each barrel structure is differently sized and configured for advancement into anal canals of different anatomic morphologies.
07/17/14
20140200387
Method and system for treatment of mobility dysfunction
Effective systems and methods for improving neural communication impairment of a vertebrate being and affecting motor activity of a peripheral body part including a first signal providing component configured to provide pulsed peripheral stimulation signals at the peripheral body part, a second signal providing component configured to provide a pulsed motor cortex stimulation signal to a motor cortex area, a substantially dc signal providing component configured to provide direct current spinal stimulation signal at a neural spinal junction and a controller component configured to control timing of the pulsed peripheral stimulation signals and the pulsed motor cortex stimulation signal.. .
07/17/14
20140200219
Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a pde-4 inhibitor, a pde-5 inhibitor, a compound that elevates cgmp and/or pkg, a stimulator of guanylyl cyclase and/or pkg, a combination of a compound that elevates cgmp, pkg or no with an antioxidant that decreases ros, or a compound that increases mmp activity..
07/17/14
20140200208
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of formula (i) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mglur2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved.
07/17/14
20140200178
Method of detection of clinically significant post-prandial hyperglycemia in normoglycemic patients
This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (ahb) in a single fasting baseline biological sample of the patient; (b) comparing the level of ahb in the single fasting baseline biological sample to a reference ahb level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b).
07/17/14
20140200177
Method of detection of occult pancreatic beta cell dysfunction in normoglycemic patients
This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (ahb) in a single fasting baseline biological sample of the patient; (b) comparing the level of ahb in the single fasting baseline biological sample to a reference ahb level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b).
07/17/14
20140199692
Translational dysfunction based therapeutics
Provided are methods and compositions for inhibiting eukaryotic translation initiation factor eif4e. Such methods and compositions may be used alone or in conjunction with other therapies, such as gene therapies, for inhibiting cell proliferation and/or treating cancer..
07/17/14
20140199315
Sp35 antibodies and uses thereof
Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (negative regulator). Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction.
07/10/14
20140194910
Vessel shaping devices and methods
Disclosed is a medical device for shaping a vessel accommodated therein in a predetermined form, wherein said vessel includes a vein and an artery which are connected at a artifactual vascular junction thereof. The device includes an external vascular support (100) having at least one vascular support wall for accommodating an exterior vessel wall of a vessel therein when implanted.
07/10/14
20140194808
Methods and systems for use of photolyzable nitric oxide donors
The present disclosure relates to methods and systems for use of photolyzable nitric oxide donors for the treatment of sexual dysfunction.. .
07/10/14
20140194754
Method and device for detecting and assessing reactive hyperemia using segmental plethysmography
A method for measuring reactive hyperemia in a subject is disclosed. The method includes performing a first segmental cuff plethysmography to generate a baseline arterial compliance curve and/or a baseline pressure-area (p-a) curve, performing a second segmental cuff plethysmography to generate a hyperemic arterial compliance curve and/or a hyperemic p-a curve, and calculating an area between the baseline and the hyperemic curves.
07/10/14
20140194471
Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine m1 receptors
In one aspect, the invention relates to substituted 1-benzylindolin-2-one analog compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/10/14
20140194353
Compositions and methods for the treatment of nervous disorders associated with diabetes
Compositions and methods for treating neural dysfunction. A exemplary method comprises administering to a subject having a neuropathy, e.g., a cognitive dysfunction or alzheimer's, a therapeutically effective amount of an insulin or insulin analog, wherein the insulin or insulin analog crosses the bbb and/or a compound that increases srebp-2 expression or activity in the cns of the subject..
07/03/14
20140188191
Implantable neurostimulator for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration
A system for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration is provided. The system includes a patient-operable external controller to transmit a plurality of unique signals.
07/03/14
20140187608
Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
The present invention relates to methods and compositions for enhancing neuronal connectivity. It is based, at least in part, on the discovery of a protein, termed “mirta22,” that inhibits the formation of structures which create connections between neurons.
07/03/14
20140187605
Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg)
The invention relates to the field of endothelial barrier dysfunction, particular, the invention relates to new methods for the treatment of endothelial barrier dysfunction, such as inflammatory edema by inhibiting abl-related gene (arg).. .
07/03/14
20140187600
Use of metabotropic glutamate receptors
The invention concerns the use an mglur modulator, e.g. An mglur5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction..
07/03/14
20140187509
Use of s-adenosylmethionine, vitamin e, and vitamin c for the prevention and treatment of cardiovascular dysfunction
The present invention provides a method of preventing or treating cardiovascular dysfunction by administering a therapeutically effective amount of (a) one or more of (i) s-adenosylmethionine or a derivative or pharmaceutically acceptable salt thereof and (ii) n-acetylcysteine or a derivative or pharmaceutically acceptable salt thereof; (b) vitamin e or a derivative or pharmaceutically acceptable salt thereof; and (c) vitamin c or a derivative or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.. .
07/03/14
20140187444
Methods and compositions for detecting and modulating o-glycosylation
The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for identifying therapeutic compounds to treat glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction.
07/03/14
20140185001
Eyewear with lens retention feature and method of manufacture
Eyewear includes a set of lenses, a frame, and a pair of arms. A primary attachment feature facilitates attachment of the arms to the frames.
06/26/14
20140179726
Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. A human) to physiological processes within the host.
06/26/14
20140179662
Pharmaceutically active disubstituted triazine derivatives
The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase..
06/26/14
20140179597
Method for the treatment and prevention of alzheimer's disease and central nervous system dysfunction
Intranasal insulin is beneficial for the treatment of alzheimer's disease and other neurologic disorders. But commercial insulin preparations use metacresol, phenol, and other preservatives for chemical stabilization.
06/26/14
20140178357
Stabilized liquid and lyophilized adamts13 formulations
The present invention relates to formulations of adamts13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of adamts13 that are suitable for pharmaceutical administration.
06/26/14
20140177891
Separate inner and outer hair cell loss compensation
A method and device for compensating sensorineural hearing loss in a manner that allows dysfunction of the inner and outer hair cells to be separately compensated is described. The disclosed techniques involve providing separately adjustable compression pathways for the received sound..
06/19/14
20140171621
Galectin-immunoglobulin chimeric molecules
Described are galectin-1/ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.. .
06/19/14
20140171477
Derivatives of celeboxib, use thereof and preparation thereof
Derivatives of celecoxib that lack cyclooxygenase inhibitory activity but have improved pde5 inhibitory activity are provided along with pharmaceutical compositions containing them for the treatment or prevention of cancer. Such compounds are expected to have reduced toxicity compared with celecoxib and other cyclooxygenase inhibitors, and greater efficacy compared with conventional pde5 inhibitors.
06/19/14
20140171442
Alicyclic[c] benzopyrone derivatives and uses thereof
Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula i or their salts.
06/19/14
20140171387
Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
Since a compound represented by formula (i) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc.
06/12/14
20140163416
In vivo device and method for researching gi tract processes, microbes, and variables associated with illnesses and diseases
An orally ingested capsule has capabilities of sampling gut substances and microbes before, during and after delivery of system perturbation substances, to the gut at any point or time. Sensors are provided to simultaneously measure, monitor, record, and transmit data in real time obtained within the exact vicinity of substance deployment and microbial assisted digestive processes occur.
06/12/14
20140163314
Apparatus, system and operation method for the treatment of female sexual dysfunction
There is disclosed an apparatus for treating a sexual dysfunctional female patient, comprising an implanted stimulation device adapted to stimulate at least a part of the sexually responsive tissue of the vulva or the wall of the vagina of the patient by movement of said stimulation device and contact between said stimulation device and the sexually responsive tissue or the wall of the vagina. A system and an operation method for the treatment of female sexual dysfunction are also disclosed..
06/12/14
20140163065
Preparation and therapeutic applications of (2s, 3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (cns).. .
06/12/14
20140163062
Remedy for psychoneurotic diseases
A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.. .
06/12/14
20140163021
Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
Candidate compounds for use in neuro-protection and repair in neurological disorders involving tau dysfunction (including alzheimer's disease) are identified from a direct interaction between proteins fkbp52 and tau. The method for screening a drug for the prevention and treatment of neurological disorders involving tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a tau polypeptide and a fkbp52 polypeptide, and selecting positively the candidate compound that modulates binding..
06/12/14
20140163017
Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
In one aspect, the invention relates to substituted (e)-n′-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including lsd1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the lsd1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..


Popular terms: [SEARCH]

Dysfunction topics: Dysfunction, Hypertension, Vascular Disease, Spinal Cord, Endothelial, Steoporosis, Endothelial Dysfunction, Nephropathy, Osteoporosis, Congestive Heart Failure, Theophylline, Sexual Dysfunction, Myocardial Infarction, Infarction, Cardiovascular Disease

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Dysfunction for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dysfunction with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4729

3859

449589 - 0 - 78